Switzerland Authorizes and Purchases Moderna's COVID-19 Vaccine

Moderna, Inc. announced the Swiss Agency for Therapeutic Products, Swissmedic, has authorized the COVID-19 Moderna Vaccine in Switzerland. The authorization is given according to the ordinary approvals procedure. It is based on a rolling submission of data and the totality of scientific evidence shared by the Company, including a data analysis from the pivotal Phase 3 clinical study announced on November 30, 2020. 

With this authorization, the Swiss Federal Government will secure 7.5 million doses of the COVID-19 Vaccine Moderna, with the first deliveries are expected to begin in Switzerland in January 2021.

Stéphane Bancel, CEO of Moderna, stated in a press release issued on January 12, 2021, “Switzerland has played a critical role in Moderna’s history since our early days, and it means a lot to us that we can now provide a highly effective vaccine to help protect the citizens of Switzerland.”

Moderna has also received authorization from regulatory authorities in the USA, Canada, Israel, the European Union, and the United Kingdom. Additional regulatory authorizations are currently under review in other countries and by the World Health Organization.